09:29 AM EDT, 07/17/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Thursday it completed a phase 1 study of elraglusib in pediatric patients, which demonstrated prolonged and durable complete responses in two of 10 refractory Ewing Sarcoma patients.

Two more patients had durable stable disease in difficult-to-treat cancer, while a partial response was observed in one patient with a desmoplastic small-round-cell tumor, the company said.

The company said it plans to advance the clinical development program towards a phase 2 study in children, adolescents and adults with relapsed/refractory Ewing Sarcoma following the end of the phase 1 portion of its clinical study, which assessed elraglusib in pediatric patients with refractory malignancies.

Shares of Actuate Therapeutics ( ACTU ) were up over 17% in recent premarket activity.